Menu

valcyte是什么药品呢?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

What kind of medicine is it? Valcyte, developed by the Swiss company Roche, is an oral anti-cytomegalovirus infection drug. This product is also the prodrug of ganciclovir and is an active ganciclovir valine ester. After oral administration, it can be rapidly hydrolyzed into ganciclovir by phosphatase in intestinal and liver cells. Its antiviral spectrum and mechanism of action are similar to ganciclovir, but its bioavailability is significantly higher than that of ganciclovir. Its oral bioavailability is 62.4%, which is 10 times that of ganciclovir, while its toxicity is greatly reduced. So what does valcyte mainly treat, and which patients can it be suitable for?

Approved by the US FDA in May 2001, Valcyte is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. Its indications were expanded in May 2003, and Valcyte is used to prevent and treat secondary CMV infection in organ transplant recipients.

On August 11, 2010, Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced that the U.S. Food and Drug Administration (FDA) approved Valcyte for the treatment of adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease. 

Launched in China in 2006, it is suitable for the treatment of patients with acquired immunodeficiency syndrome (AIDS) combined with cytomegalovirus (CMV) retinitis and the prevention of CMV infection in high-risk solid organ transplant patients.

  Dosage and Administration: Adult patients should use valcyte tablets rather than valcyte oral solution. Oral solutions and tablets should be taken with food. Valcyte agent should not be broken or crushed. Before dispensing the medication to a patient, the pharmacist must prepare an oral solution (50 mg/ml) with valcyte.

Treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily. The above are the main indications of valcyte. I hope it can help everyone. If you have any other questions about it, you can also consult the medical companion Hattori.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。